NCT00550342View on ClinicalTrials.gov

Rituximab Treatment of Focal Segmental Glomerulosclerosis

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2008

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Focal Segmental Glomerulosclerosis (FSGS)
Interventions
DRUG

rituximab

375 mg/m2 intravenously for 4 doses

Trial Locations (1)

46202

Indiana University, Indianapolis

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Indiana University

OTHER

lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

NCT00550342 - Rituximab Treatment of Focal Segmental Glomerulosclerosis | Biotech Hunter | Biotech Hunter